You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

COVID-19 Management in Pediatrics: An Update on Treatment in Pediatric Outpatients

  • Authors: Monique Soileau-Burke, MD, IBCLC, FAAP; Aimee M. Dassner, PharmD, BCIDP
  • CME / ABIM MOC / CE Released: 4/21/2022
  • Valid for credit through: 4/21/2023
Start Activity

  • Credits Available

    Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.50 ABIM MOC points

    Nurses - 0.50 ANCC Contact Hour(s) (0.5 contact hours are in the area of pharmacology)

    Pharmacists - 0.50 Knowledge-based ACPE (0.050 CEUs)

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for pediatricians, infectious disease/HIV specialists, emergency medicine physicians, primary care physicians (PCPs), nurse practitioners (NPs), physician assistants (PAs), nurses, pharmacists, and other practice providers in outpatient settings involved in the management of pediatric patients with COVID-19.

The goal of this activity is that learners will be better able to understand the Emergency Use Authorization (EUA) treatment options for COVID-19 in pediatric patients and have improved confidence in identifying pediatric patients who are at risk of developing severe disease.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Neutralizing monoclonal antibody therapeutics with EUAs for SARS-CoV-2 in pediatric patients 
    • Current outpatient treatment options for pediatric patients with COVID-19
  • Have greater competence in their ability to
    • Assess risk of severe COVID-19 in pediatric patients
  • Demonstrate greater confidence in their ability to
    • Communicate with patients/parents/caregivers about treatment options for pediatric patients with COVID-19


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Medscape policies. Others involved in the planning of this activity have no relevant financial relationships.

Disclosures for additional planners can be found here.


Faculty

  • Monique Soileau-Burke, MD, IBCLC, FAAP

    Vice-President, Maryland American Academy of Pediatrics  
    The Pediatric Center, LLC  
    Columbia, Maryland

    Disclosures

    Disclosure:  Monique Soileau-Burke, MD, IBCLC, FAAP, has no relevant financial relationships.

  • Aimee M. Dassner, PharmD, BCIDP

    Clinical Pharmacy Specialist
    Infectious Diseases and Antimicrobial Stewardship
    Children's National Hospital
    Washington, DC

    Disclosures

    Disclosure: Aimee M. Dassner, PharmD, BCIDP, has no relevant financial relationships.

Editors

  • Maria B. Uravich, BSc, ELS

    Medical Education Director, Medscape, LLC

    Disclosures

    Disclosure: Maria B. Uravich, BSc, ELS, has no relevant financial relationships.

  • Yoji Yamaguchi, MA, ELS

    Scientific Content Manager, Medscape, LLC

    Disclosures

    Disclosure: Yoji Yamaguchi, MA, ELS, has no relevant financial relationships. 

Compliance Reviewer

  • Stephanie Corder, ND, RN, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC 

    Disclosures

    Disclosure: Stephanie Corder, ND, RN, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

    For Nurses

  • Awarded 0.50 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.50 contact hours are in the area of pharmacology.

    Contact This Provider

    For Pharmacists

  • Medscape designates this continuing education activity for 0.50 contact hour(s) (0.050 CEUs) (Universal Activity Number: JA0007105-0000-22-064-H06-P).

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

COVID-19 Management in Pediatrics: An Update on Treatment in Pediatric Outpatients

Authors: Monique Soileau-Burke, MD, IBCLC, FAAP; Aimee M. Dassner, PharmD, BCIDPFaculty and Disclosures

CME / ABIM MOC / CE Released: 4/21/2022

Valid for credit through: 4/21/2023

processing....

Note: The information on the coronavirus outbreak is continually evolving. The content within this activity serves as a historical reference to the information that was available at the time of this publication. We continue to add to the collection of activities on this subject as new information becomes available. Members should consult FDA.gov or local resources for current information about authorized interventions. It is the policy of Medscape Education to avoid the mention of brand names or specific manufacturers in accredited educational activities. However, manufacturer names related to authorized COVID-19 vaccines and/or therapeutics are provided in this activity in an effort to promote clarity. The use of manufacturer names should not be viewed as an endorsement by Medscape of any specific product or manufacturer.  

Educational Impact Challenge

The goal of this activity is that learners will be better able to understand the Emergency Use Authorization (EUA) treatment options for COVID-19 in pediatric patients and have improved confidence in identifying pediatric patients who are at risk of developing severe disease.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.